Analyst Price Targets — JANX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 16, 2026 11:55 am | Kelsey Goodwin | Piper Sandler | $30.00 | $13.72 | TheFly | Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler |
| December 17, 2025 10:58 am | — | Barclays | $29.00 | $14.65 | TheFly | Janux Therapeutics price target lowered to $29 from $48 at Barclays |
| December 2, 2025 12:40 pm | David Dai | UBS | $57.00 | $17.28 | StreetInsider | Janux Therapeutics (JANX) Reiterated at Buy by UBS After JANX007 Ph1 update |
| December 2, 2025 12:15 pm | Stephen Willey | Stifel Nicolaus | $38.00 | $33.99 | TheFly | Janux Therapeutics price target lowered to $38 from $46 at Stifel |
| December 2, 2025 11:11 am | — | H.C. Wainwright | $45.00 | $33.99 | TheFly | Janux Therapeutics price target lowered to $45 from $70 at H.C. Wainwright |
| September 16, 2025 8:51 pm | — | Barclays | $47.00 | $23.41 | TheFly | Janux Therapeutics initiated with an Overweight at Barclays |
| September 10, 2025 9:12 am | — | Stifel Nicolaus | $45.00 | $24.31 | TheFly | Janux Therapeutics resumed with a Buy at Stifel |
| September 3, 2025 8:25 pm | Brad Canino | Guggenheim | $72.00 | $23.04 | TheFly | Janux Therapeutics initiated with a Buy at Guggenheim |
| July 11, 2025 10:46 am | Sean McCutcheon | Raymond James | $65.00 | $25.15 | TheFly | Janux Therapeutics initiated with an Outperform at Raymond James |
| February 28, 2025 2:55 pm | — | Scotiabank | $41.00 | $32.89 | TheFly | Janux Therapeutics price target lowered to $41 from $62 at Scotiabank |
Latest News for JANX
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The past year marked a period of significant execution and progress for Janux as we continued to translate the…
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011.
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced that William Go, M.D., Ph.D., has been appointed Chief Medical Officer, effective January…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JANX.
U.S. House Trading
No House trades found for JANX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.